1.

接受PegIFN治疗的CHB患者基线情况

Baseline characteristics of the patients receiving PegIFN treatment

Characteristics	Control group (n=114)	Intervention group (n=51)
*P < 0.05, compared with control group. ALT, alanine aminotransferase. AST, aspartate aminotransferase. ALB, albumin. Tbil, total bilirubin.
Gender Male (%)	64 (56.1%)	43 (84.3%)*
Age (year, Mean±SD)	28.8±5.3	33.2±5.9
Compensated cirrhosis (n, %)	10 (8.8%)	4 (7.8%)
ALT (U/L, Mean±SD)	68.5±16.3	82.4±18.2
AST (U/L, Mean±SD)	46.2±10.4	50.7±12.2
ALB (g/L, Mean±SD)	45.5±4.0	42.6±3.6
Tbil (μmol/L, Mean±SD)	13.3±4.2	14.2±3.9
Log HBVDNA (Mean±SD)	5.6±0.9	5.9±0.5